Last reviewed · How we verify
Co-Codamol
Acts as a weak agonist at the mu-opioid receptor and a weak antagonist at the kappa-opioid receptor.
Acts as a weak agonist at the mu-opioid receptor and a weak antagonist at the kappa-opioid receptor. Used for Pain relief.
At a glance
| Generic name | Co-Codamol |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor, Kappa-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 2 |
Mechanism of action
This dual action is thought to contribute to its analgesic and anti-anxiety effects.
Approved indications
- Pain relief
Common side effects
- Nausea
- Dizziness
- Constipation
Key clinical trials
- Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304) (PHASE2)
- Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control (PHASE2)
- CBD for Dental Pain (PHASE1, PHASE2)
- Paracetamol Vs Caffeine Vs Codeine in the Management of Post Traumatic Pain in Emergencies (PHASE3)
- An Randomized Control Trial Comparing Two Drug Combinations for Pain Management After Third Molars Surgery (NA)
- Erector Spinae Plane Block Versus Paravertebral Block (NA)
- Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee (PHASE2)
- A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |